UNSPSC 51283604: Rifaximin

This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L36O5T016N. European Medicines Agency schedules Rifaximin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10312MIG. Rifaximin generally arises in the molecular formula C43H51N3O11.

The term RIFAXIMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) RIFAXIMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifaximin under HS 29419000 and SITC 54139. As of Q4 2014, RIFAXIMIN remains the US FDA Preferred Term for this commodity. Rifaximin bears US NLM identifiers UMLS ID C0073374 and NCI Concept Code C61926.

UNSPSC 51283604 Rifaximin, a Commodity code, nominally covers individual pharmaceutical products, though recent state and local activity under this code shows minimal alignment with rifaximin itself. State and local governments soliciting under related pharmaceutical procurement codes are acquiring broad classes of medications—including antimicrobial tablets, opioid antagonists, and drug deactivation systems—through piggyback contracts and competitive bidding processes tied to public health initiatives, emergency preparedness, and community health programs. Issuing bodies include state health departments and county public health authorities, which use cooperative purchasing consortiums such as MMCAP to aggregate purchasing power and leverage existing pharmaceutical warehouse contracts. The work involves securing reliable supply chains for medications with specific shelf-life requirements, coordinating quarterly or as-needed deliveries, and ensuring vendor compliance with drug-free workplace certification, E-Verify, and applicable federal regulations when procurement is funded through FEMA or similar programs.

Recent opportunities reflect activity in Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Bid 26-482DPH-PREPD-B-53392) for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets, totaling $2,999,999.11 over a 12-month initial term with two renewal options. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, featuring a two-year initial term with one-year renewal option and a three-month probationary termination period. Neither opportunity explicitly involves rifaximin; the code's recent-opportunities block contains no active rifaximin-specific solicitations.